



Bin Liu, Ph.D., is a Scientific Director at WuXi AppTec, specializing in metabolic disease drug discovery and in vitro pharmacology. He brings extensive experience spanning academia, biotech, and pharmaceutical R&D, with expertise in metabolic biology, translational research, and early drug discovery. Prior to joining WuXi AppTec, Bin worked at Novo Nordisk, where he led early-stage drug discovery projects across metabolic and rare diseases. He has also conducted research in cancer metabolism and published in leading scientific journals including Science, Cell Research, Nature Communications, Cell Reports as both the first and the corresponding authors. At WuXi AppTec, he focuses on advancing innovative in vitro and translational platforms to support metabolic drug discovery.